Why have transgenic rodent models failed to successfully mimic Alzheimer's disease. How can we develop effective drugs without them?

Expert Opin Drug Discov. 2019 Apr;14(4):327-330. doi: 10.1080/17460441.2019.1581169. Epub 2019 Feb 18.

Rafael Franco^{1

2}, Eva Martínez-Pinilla^{3

4

5}, Gemma Navarro^{2

6}

¹ a Department of Biochemistry and Molecular Biomedicine, Faculty of Biology , Universitat de Barcelona , Barcelona , Spain.
² b CiberNed: Centro de Investigación en Red, enfermedades Neurodegenerativas , Instituto de Salud Carlos III , Madrid , Spain.
³ c Departamento de Morfología y Biología Celular, Facultad de Medicina , Universidad de Oviedo , Asturias , Spain.
⁴ d Instituto de Neurociencias del Principado de Asturias (INEUROPA) , Asturias , Spain.
⁵ e Instituto de Salud del Principado de Asturias (ISPA) , Asturias , Spain.
⁶ f Department of Biochemistry and Physiology, Faculty Pharmacy and Food Sciences , Universitat de Barcelona , Barcelona , Spain.

No abstract available

Keywords: AD patient; NMR; cognition enhancer; epidemiology; fMRI; memory enhancer; nootropics.

Publication types